---
title: "12 Health Care Stocks Moving In Tuesday's Pre-Market Session"
description: "In Tuesday's pre-market session, Polaryx Therapeutics (PLYX) saw a significant gain of 103.3%, reaching $4.9, while Masimo (MASI) rose 34.14% to $174.59. Other gainers included Compass Pathways (CMPS)"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276121189.md"
published_at: "2026-02-17T12:05:54.000Z"
---

# 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

> In Tuesday's pre-market session, Polaryx Therapeutics (PLYX) saw a significant gain of 103.3%, reaching $4.9, while Masimo (MASI) rose 34.14% to $174.59. Other gainers included Compass Pathways (CMPS) up 18.93%, Ernexa Therapeutics (ERNA) up 17.77%, and Alpha Cognition (ACOG) up 14.75%. Conversely, Ocular Therapeutix (OCUL) dropped 26.9% to $6.49, followed by AIM ImmunoTech down 14.4%, Picard Medical down 13.47%, and Quince Therapeutics down 11.26%.

### Gainers

-   **Polaryx Therapeutics** (NASDAQ:PLYX) stock increased by 103.3% to $4.9 during Tuesday's pre-market session. The market value of their outstanding shares is at $114.0 million.
-   **Masimo** (NASDAQ:MASI) stock increased by 34.14% to $174.59. The company's market cap stands at $7.0 billion.
-   **Compass Pathways** (NASDAQ:CMPS) stock rose 18.93% to $6.91. The market value of their outstanding shares is at $543.5 million.
-   **Ernexa Therapeutics** (NASDAQ:ERNA) shares rose 17.77% to $0.38. The company's market cap stands at $2.5 million.
-   **Alpha Cognition** (NASDAQ:ACOG) stock moved upwards by 14.75% to $5.6. The market value of their outstanding shares is at $106.1 million.
-   **XTL Biopharmaceuticals** (NASDAQ:XTLB) shares moved upwards by 12.11% to $1.0. The market value of their outstanding shares is at $8.4 million.

### Losers

-   **Ocular Therapeutix** (NASDAQ:OCUL) shares decreased by 26.9% to $6.49 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.9 billion.
-   **AIM ImmunoTech** (AMEX:AIM) stock declined by 14.4% to $1.07. The company's market cap stands at $4.0 million.
-   **Picard Medical** (AMEX:PMI) shares fell 13.47% to $1.35. The market value of their outstanding shares is at $114.9 million.
-   **Quince Therapeutics** (NASDAQ:QNCX) stock fell 11.26% to $0.18. The market value of their outstanding shares is at $11.1 million.
-   **SCWorx** (NASDAQ:WORX) stock fell 10.85% to $0.25. The company's market cap stands at $4.4 million.
-   **Strata Skin Sciences** (NASDAQ:SSKN) stock fell 10.15% to $0.31. The market value of their outstanding shares is at $2.0 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ERNA.US - Ernexa Therapeutics](https://longbridge.com/en/quote/ERNA.US.md)
- [ACOG.US - Alpha Cognition](https://longbridge.com/en/quote/ACOG.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [CMPS.US - Compass Pathways](https://longbridge.com/en/quote/CMPS.US.md)
- [XHE.US - SPDR S&P Health Equip](https://longbridge.com/en/quote/XHE.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [PLYX.US - Polaryx Therapeutics](https://longbridge.com/en/quote/PLYX.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [IHI.US - iShares US Medical Devices](https://longbridge.com/en/quote/IHI.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 小型股 Polaryx 選擇了研究合作伙伴，其股票因計劃進行第二階段試驗而大幅上漲 | Polaryx Therapeutics（納斯達克代碼：PLYX）股價上漲 46.06%，至 3.52 美元，此次上漲是由於其選擇了一家研究機構進行 SOTERIA 第二階段臨牀試驗。該試驗將評估 PLX-200 在溶酶體儲存疾病中的安全性 | [Link](https://longbridge.com/en/news/276143893.md) |
| Assetmark Inc. 出售了波士頓科學公司 82,501 股股票 $BSX | Assetmark Inc. 已將其在波士頓科學公司（NYSE:BSX）的持股減少了 41.6%，在第三季度出售了 82,501 股。出售後，Assetmark 持有 115,613 股，估值約為 1129 萬美元。包括先鋒集團和道富銀行在 | [Link](https://longbridge.com/en/news/276044910.md) |
| Compass Pathways 在治療難治性抑鬱症方面的成功點燃了投資者的熱情 | COMPASS Pathways 的股票在盤前交易中上漲了 23.06%，達到 7.15 美元，此前該公司宣佈其針對難治性抑鬱症的第三階段 COMP006 試驗取得成功。該試驗顯示，25 毫克 COMP360 劑量在症狀嚴重程度上有顯著降低 | [Link](https://longbridge.com/en/news/276135784.md) |
| GSA Capital Partners LLP 增加了對默克公司（Merck & Co., Inc.）股票的持有量 $MRK | GSA Capital Partners LLP 在第三季度將其在默克公司的股份增加了 107.8%，目前持有 24,809 股，價值 208 萬美元。其他機構投資者也增加了他們的持股。內部人士的銷售包括首席醫學官 Chirfi Guind | [Link](https://longbridge.com/en/news/276119315.md) |
| Jefferies 重申對諾華製藥（NOVN）的持有評級 | Jefferies 分析師 James Vane 對諾華製藥 (NOVN) 重申了持有評級，目標價為 110.00 瑞士法郎。專注於醫療保健領域的 Vane 在他的股票推薦中平均回報率為 -1.0%，成功率為 49.13%。此外，DZ BA | [Link](https://longbridge.com/en/news/276102881.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.